thought follow call
combin uninspir result confus
guidanc inclus full year upjohn blend consensu put
pressur share today model continu reflect close upjohn deal
howev rais adjust ep assum
favor margin sg save think step-up top-lin growth
clear posit guidanc compound-annual-growth-rate given transit concentr
biopharma rais risk profil inde ibranc major contributor outer
year addit sale adjuv breast cancer palla readout earli
near term face mute cyclin-depend kinas class growth
price headwind see upsid vyndaqel q/q given low attr-cm
drive top-lin growth alon henc bd busi develop
need loe loss exclus period lack share repo
like limit dividend rais add deal capac overal think pfizer
stori still evolv matur pipelin investor day march uncertainti
durabl core biopharma busi keep us neutral po
announc tanezumab file us
await fda accept regulatori submiss eu/japan continu
pursu ibranc penelope-b phase readout expect late
palla expect earli abrocitinib
jade compar vs dupix expect come month vs spring
prior gene therapi expect start phase program hemophilia
dmd duchenn muscular dystrophi reflect modest consensu
expect peak
updat model forecast revenu
respect new non-gaap
ep estim vs respect
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global biopharmaceut compani
diversifi portfolio product pipelin
candid one largest pharma
compani world measur market
capit revenu compon
jone industri averag
shed low growth busi divis
upjohn consum focus higher
growth innov busi compani look
return growth serv base
year revenu grow howev key
pipelin win necessari second wave
put growth risk
neutral await transact
close pipelin matur off-set
million
remainco base blend averag dcf analysi
price-to-earnings multipl base larg cap global therapeut group dcf use
wacc termin valu intrins valu price-to-earnings analysi
assum multipl ep estim vs peer larg reflect
higher growth expect yield intrins valu support po
downsid risk sale downsid would expect share declin upcom data
prevnar ibranc posit inabl pipelin overcom patent loe
 transact perceiv valu destruct
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
